Why did Shuttle's operating expenses surge in Q3 2024?

The operating expenses of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) in Q3 2024 are not currently available. However, we can infer some possible reasons for the increase in operating expenses based on the relevant information.

1. **Clinical Trial Expansion**: Shuttle Pharma has been expanding its clinical trial sites for the Phase 2 trial of Ropidoxuridine, which could have led to increased operating expenses related to site preparation, patient enrollment, and trial operations. The company has entered into agreements with multiple site locations to administer the trial, which may have required additional resources and expenses.
2. **Regulatory Compliance Costs**: Shuttle Pharma had previously received a notice of non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the company's failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024. The process of regaining compliance with Nasdaq listing rules, including filing the amended financial reports, could have incurred significant costs.

In conclusion, the operating expenses of Shuttle Pharma in Q3 2024 may have surged due to the expansion of clinical trials and the costs associated with regaining compliance with Nasdaq listing rules.